VINCVincerx Pharma, Inc.

VINC Stock Price, Valuation & Chart | Vincerx Pharma, Inc.

Compare

$0.010+0.00 (+0.00%)

At close · 01 Sept 2026, 02:31 pm

Sector: Healthcare Industry: Biotechnology VINC intrinsic value VINC calculated fair value vs price

Overview Financials Dividends Ratios

VINC Historical price chart

VINC Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization68.57K

PE Ratio0.0

EPS-5.79

Trading Volume614

Today's High/Low0.01/0.01

Dividend Yield0.00

52 Week High/Low1.43/0.0

Shares Outstanding5.23M

VINC Financial Statement

VINC Analyst ratings

VINC Analysis & performance metrics

VINC Company profile

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United…

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9…

VINC Management team

Name

Position

Raquel E. Izumi Ph.D.CEO

Co-Founder, Acting Chief Executive Officer, Secretary & Director

Tom C. Thomas J.D.

Consultant

Melissa Merrick SPHRCTO

Senior Director of People & Culture and Head of Human Resource

Beatrix Stelte-Ludwig Ph.D.

Executive Chief Development Officer

John C. Byrd M.D.

Founder & Chairman of Scientific Advisory Board

Alexander A. Seelenberger M.B.A.

Consultant

Gabriela Jairala

Vice President of Investor Relations & Corporate Communications and Chief of Staff

Kevin HaasCFO

Acting Chief Financial Officer, Vice President of Finance & Corporate Controller

Name

Position

Raquel E. Izumi Ph.D.CEO

Co-Founder, Acting Chief Executive Officer, Secretary & Director

Tom C. Thomas J.D.

Consultant

Melissa Merrick SPHRCTO

Senior Director of People & Culture and Head of Human Resource

Beatrix Stelte-Ludwig Ph.D.

Executive Chief Development Officer

John C. Byrd M.D.

Founder & Chairman of Scientific Advisory Board

Alexander A. Seelenberger M.B.A.

Consultant

Gabriela Jairala

Vice President of Investor Relations & Corporate Communications and Chief of Staff

Kevin HaasCFO

Acting Chief Financial Officer, Vice President of Finance & Corporate Controller

Management Team

Raquel E. Izumi Ph.D.CEO

Co-Founder, Acting Chief Executive Officer, Secretary & Director

Tom C. Thomas J.D.

Consultant

Melissa Merrick SPHRCTO

Senior Director of People & Culture and Head of Human Resource

Beatrix Stelte-Ludwig Ph.D.

Executive Chief Development Officer

John C. Byrd M.D.

Founder & Chairman of Scientific Advisory Board

Alexander A. Seelenberger M.B.A.

Consultant

Gabriela Jairala

Vice President of Investor Relations & Corporate Communications and Chief of Staff

Kevin HaasCFO

Acting Chief Financial Officer, Vice President of Finance & Corporate Controller

Management

Raquel E. Izumi Ph.D.CEO

Co-Founder, Acting Chief Executive Officer, Secretary & Director

Tom C. Thomas J.D.

Consultant

Melissa Merrick SPHRCTO

Senior Director of People & Culture and Head of Human Resource

Beatrix Stelte-Ludwig Ph.D.

Executive Chief Development Officer

John C. Byrd M.D.

Founder & Chairman of Scientific Advisory Board

Alexander A. Seelenberger M.B.A.

Consultant

Gabriela Jairala

Vice President of Investor Relations & Corporate Communications and Chief of Staff

Kevin HaasCFO

Acting Chief Financial Officer, Vice President of Finance & Corporate Controller

Total 8 executives

VINC Frequently asked questions

What is Vincerx Pharma, Inc. (VINC) Stock Price?

Current stock price of Vincerx Pharma, Inc. (VINC) stock is $0.010. The stock price is +0.00% higher in the session. The intraday range can be seen from this page. Volume of Vincerx Pharma, Inc. (VINC) stock is 614.

Last updated at 01 Sept 2026, 02:31 pm.

Why is the Vincerx Pharma, Inc. (VINC) stock price going up or down today?

The stock price of Vincerx Pharma, Inc. (VINC) can change with earnings, company news, and overall market sentiment. Vincerx Pharma, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Vincerx Pharma, Inc. stock expensive at its current price?

Whether Vincerx Pharma, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for VINC on this page is 0.00. EPS on this page is -5.79. Compare those figures with peers and growth expectations before deciding if the current Vincerx Pharma, Inc. price is justified.

How has the stock price of Vincerx Pharma, Inc. (VINC) performed historically?

Historical performance for Vincerx Pharma, Inc. (VINC) is shown on the price chart on this page. Review multi-period moves alongside volume to see how VINC reacted to past earnings and market events.

Should I buy Vincerx Pharma, Inc. (VINC) stock, at this price?

Buying Vincerx Pharma, Inc. (VINC) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.